US Broker Ratings

Crinetics Pharmaceuticals (CRNX) Stock Analysis: Unpacking a 105% Potential Upside for Growth Investors

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is capturing the attention of growth-oriented investors with its compelling development pipeline and an eye-catching potential upside of 105.26%. The company, headquartered in San Diego,..

ICU Medical, Inc. (ICUI) Investor Outlook: A 24% Upside Potential Amid Healthcare Innovation

ICU Medical, Inc. (NASDAQ: ICUI) presents a compelling opportunity for investors seeking exposure in the healthcare sector, particularly within the medical instruments and supplies industry. With a market capitalization of..

ImmunityBio, Inc. (IBRX) Stock Analysis: A Biotech Powerhouse with 29% Upside Potential

ImmunityBio, Inc. (NASDAQ: IBRX) stands as a formidable player in the biotechnology sector, capturing investor interest with its innovative approach to immunotherapy. With a market cap of $10.73 billion, this..

Select Medical Holdings Corp (SEM) Stock Analysis: Discover the 14.27% Potential Upside in Healthcare

Select Medical Holdings Corporation (NYSE: SEM) stands as a formidable entity within the healthcare sector, particularly in the medical care facilities industry. With a market capitalization of $1.86 billion, this..

Addus HomeCare Corporation (ADUS) Stock Analysis: Potential 33% Upside for Savvy Investors

Addus HomeCare Corporation (NASDAQ: ADUS) stands as a notable player in the healthcare sector, specifically within the medical care facilities industry. With a market capitalization of $1.95 billion, Addus is..

Enovis Corporation (ENOV): Investor Outlook on a Promising 75.8% Potential Upside

Investors seeking opportunities in the healthcare sector may find Enovis Corporation (ENOV) an intriguing choice, especially with a potential upside of 75.8% as indicated by the average target price set..

Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Promising Biotech with 35.82% Upside Potential

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical leader in rare and orphan diseases, is making waves in the biotechnology sector with its innovative therapies and robust growth prospects. With a..

Bausch Health Companies Inc. (BHC) Stock Analysis: Unveiling a Potential 29.65% Upside

Bausch Health Companies Inc. (NYSE: BHC), a diversified specialty pharmaceutical and medical device company headquartered in Laval, Canada, is a name that has long been associated with dynamic growth and..

Metsera, Inc. (MTSR) Stock Analysis: Biotechnology Innovator Faces Potential Downside Despite Strong Buy Ratings

Metsera, Inc. (MTSR), a clinical-stage biotechnology company based in New York, is making waves in the healthcare sector with its promising pipeline of hormone analog peptides targeting obesity, overweight conditions,..

CRISPR Therapeutics AG (CRSP) Investor Outlook: Biotechnology Innovator Poised for a 39.51% Upside

CRISPR Therapeutics AG (NASDAQ: CRSP) stands as a compelling player in the biotechnology sector, with its innovative focus on gene editing technologies. This Swiss company has captured investors’ attention due..

Arrowhead Pharmaceuticals, Inc. (ARWR)

⚠️ No article content returned.

..

Tarsus Pharmaceuticals (TARS) Stock Analysis: Strong Buy Ratings and 21.88% Upside Potential

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) stands at the forefront of the biopharmaceutical industry with a primary focus on eye care therapeutics. The company’s strategic developments and market performance have captured..

HUTCHMED (China) Limited (HCM) Stock Analysis: Potential Upside of 51.89% Amid Unique Growth Opportunities

HUTCHMED (China) Limited (HCM), a prominent player in the healthcare sector, specifically within the specialty and generic drug manufacturing industry, presents an intriguing investment opportunity with a significant potential upside..

Warby Parker Inc. (WRBY) Investor Outlook: Eyeing a 9.04% Upside with Strong Buy Ratings

Warby Parker Inc. (NYSE: WRBY) is shaping up as an intriguing opportunity for investors in the healthcare sector, specifically within the Medical Instruments & Supplies industry. With a market capitalization..

Denali Therapeutics Inc. (DNLI) Investor Outlook: Analyzing the 56.80% Potential Upside

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company at the forefront of developing treatments for neurodegenerative and lysosomal storage diseases, is capturing investor attention with a compelling potential upside of..

Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating the Biotech Sector with a 23.7% Revenue Growth

Amicus Therapeutics, Inc. (NASDAQ: FOLD) has been making waves in the biotechnology industry, a sector known for its potential to deliver transformative healthcare solutions and significant financial returns. With a..

Vericel Corporation (VCEL) Stock Analysis: Exploring a 56.76% Potential Upside in Biotech

Vericel Corporation (NASDAQ: VCEL), a dynamic player in the biotechnology sector, offers a captivating prospect for investors with its focus on innovative cellular therapies and specialty biologic products. Headquartered in..

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: Navigating a Challenging Landscape with Insights into Valuation and Dividend Potential

DENTSPLY SIRONA Inc. (NASDAQ: XRAY), a key player in the medical instruments and supplies industry, commands attention with its robust market presence in the healthcare sector. With a market capitalization..

Certara, Inc. (CERT) Stock Analysis: Exploring a 38% Potential Upside in Health Information Services

Certara, Inc. (NASDAQ: CERT), a notable player in the healthcare sector, offers a compelling narrative with its technology-driven services and software products designed for biosimulation. As the healthcare industry continues..

Apogee Therapeutics (APGE) Stock Analysis: Exploring a 47.76% Potential Upside in the Biotech Sector

Apogee Therapeutics, Inc. (NASDAQ: APGE) is a promising name in the biotechnology industry, boasting a market capitalization of $4.84 billion. Operating within the healthcare sector, Apogee is headquartered in Waltham,..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds